Imugene Ltd (ASX: IMU) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Imugene Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $275.22 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 7.57 billion
Earnings per share -0.021
Dividend per share N/A
Year To Date Return -65.45%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Imugene Ltd (ASX: IMU)
    Latest News

    a doctor with stethoscope around neck sits as a computer with head in hand, looking despondent.
    Share Fallers

    Why the Imugene (ASX:IMU) share price is tumbling 7%

    It has been a mixed day for Imugene shares...

    Read more »

    Group of Imugene scientists cheering in the lab after the company received another patent for HER-Vaxx
    Share Gainers

    Imugene (ASX:IMU) share price surges 7% as R&D efforts increase

    Shares in the Aussie cancer treatment company are surging on Monday

    Read more »

    white arrow pointing down
    Share Market News

    Why Emerge Gaming, Imugene, Mesoblast, & Nick Scali shares are dropping

    These ASX shares are out of form on Thursday...

    Read more »

    four excited doctors with their hands in the air
    Share Gainers

    Why the Imugene (ASX:IMU) share price is charging higher on Thursday

    This biotech share is on the rise on Thursday...

    Read more »

    A stressed woman with her head in her hands sits at her desk reading about falling ASX 200 mining shares on her laptop
    Share Fallers

    Why AVZ Minerals, Imugene, Pointerra, & Resolute shares are dropping

    It hasn't been a good day for these ASX shares...

    Read more »

    woman in lab coat conducting testing representing biotech
    Share Market News

    Capital keeps flowing into ASX Biotech shares in 2021

    What is driving capital inflow into ASX biotech shares?

    Read more »

    share price dropping
    Share Fallers

    Why BARD1, Imugene, Northern Star, & Silver Lake shares are sinking

    It hasn't been a good day for these ASX shares...

    Read more »

    Investor with palm up and graphic illustration of asx small cap tech shares charts shooting from his hand
    ⏸️ ASX Shares

    The 5 best ASX shares of FY21 revealed

    With perfect hindsight, or a time machine, these are the 5 companies to have invested in last year.

    Read more »

    three excited doctors with hands in the air
    Healthcare Shares

    The 5 best performing ASX healthcare shares of FY21, did yours make the cut?

    These ASX shares had the healthiest gains in the last financial year...

    Read more »

    woman in lab coat conducting testing representing biotech
    Healthcare Shares

    How these top ASX biotech shares performed in FY21

    What company was the ASX's best performing biotech share over FY21?

    Read more »

    high share price
    Share Gainers

    Why a2 Milk, Chalice Mining, IDP Education, & Imugene are charging higher

    These ASX shares are ending the week strongly...

    Read more »

    stock market gaining
    Best Shares

    Here are the 5 best performing ASX All Ords shares from FY21

    Imugene was the best performing All Ords share for FY21....

    Read more »

    Frequently Asked Questions

    Imugene does not pay dividends at this stage. 

    Imugene Ltd (ASX: IMU) listed on the ASX on 24 November 1993.

    IMU ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Imugene Ltd

    Imugene Ltd (ASX: IMU) is a biotechnology company working in cancer immunotherapy.

    The company specialises in clinical-stage immuno-oncology therapies. Its product pipeline includes Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard-care drugs and immunotherapies.

    The company's lead product is HER-Vaxx, a proprietary cancer vaccine for the treatment of gastric and breast cancer, where the cancer is HER-2 positive. The vaccine has demonstrated it stimulates a polyclonal antibody response to HER2/neu. 

    Imugene's various immunotherapy products are involved in ongoing clinical trials involving cancer specialists and researchers worldwide.

    IMU Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    23 Dec 2024 $0.04 $0.00 0.00% 8,941,450 $0.04 $0.04 $0.04
    20 Dec 2024 $0.04 $0.00 0.00% 13,295,359 $0.04 $0.04 $0.04
    19 Dec 2024 $0.04 $0.00 0.00% 14,581,638 $0.04 $0.04 $0.04
    18 Dec 2024 $0.04 $0.00 0.00% 8,346,749 $0.04 $0.04 $0.04
    17 Dec 2024 $0.04 $0.00 0.00% 6,179,996 $0.04 $0.04 $0.04
    16 Dec 2024 $0.04 $0.00 0.00% 13,301,017 $0.04 $0.04 $0.04
    13 Dec 2024 $0.04 $0.00 0.00% 7,071,023 $0.04 $0.04 $0.04
    12 Dec 2024 $0.04 $0.00 0.00% 14,482,883 $0.04 $0.04 $0.04
    11 Dec 2024 $0.04 $0.00 0.00% 20,312,321 $0.04 $0.04 $0.04
    10 Dec 2024 $0.04 $0.00 0.00% 5,432,216 $0.04 $0.04 $0.04
    09 Dec 2024 $0.04 $0.00 0.00% 9,881,013 $0.04 $0.04 $0.04
    06 Dec 2024 $0.04 $0.00 0.00% 18,460,644 $0.04 $0.04 $0.04
    05 Dec 2024 $0.04 $0.00 0.00% 27,652,698 $0.04 $0.04 $0.04
    04 Dec 2024 $0.04 $0.00 0.00% 40,813,474 $0.04 $0.04 $0.04
    03 Dec 2024 $0.04 $0.00 0.00% 9,729,505 $0.04 $0.04 $0.04
    02 Dec 2024 $0.04 $0.00 0.00% 10,114,522 $0.04 $0.04 $0.04
    29 Nov 2024 $0.04 $0.00 0.00% 3,498,605 $0.04 $0.04 $0.04
    28 Nov 2024 $0.04 $0.00 0.00% 11,950,068 $0.04 $0.04 $0.04
    27 Nov 2024 $0.04 $0.00 0.00% 15,641,203 $0.04 $0.04 $0.04
    26 Nov 2024 $0.04 $0.00 0.00% 7,251,618 $0.04 $0.04 $0.04
    25 Nov 2024 $0.04 $0.00 0.00% 11,101,427 $0.04 $0.04 $0.04

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    01 Jul 2024 Leslie (Mi Ok) Chong Transfer 1,500,000 $82,500
    As advised by the company. Transfer from direct to indirect holding
    01 Jul 2024 Leslie (Mi Ok) Chong Exercise 5,793,750 $318,656
    Conversion of securities. 17,381,250 RIGHTS
    01 Jul 2024 Leslie (Mi Ok) Chong Transfer 1,500,000 $82,500
    As advised by the company. Transfer from direct to indirect holding
    01 Jul 2024 Leslie (Mi Ok) Chong Buy 5,793,750 $318,656
    Conversion of securities.
    01 Jul 2024 Paul Hopper Exercise 975,375 $53,645
    Conversion of securities. 2,926,125 PERFORMANCE RIGHTS AWARD
    01 Jul 2024 Paul Hopper Issued 975,375 $53,645
    Conversion of securities.
    01 Jul 2024 Lesley Russell Exercise 250,000 $13,750
    Conversion of securities. 750,000 - Restricted Stock Units
    01 Jul 2024 Lesley Russell Issued 250,000 $13,750
    Conversion of securities.
    01 Jul 2024 Jens Eckstein Exercise 250,000 $13,750
    Conversion of securities. 750,000 RSU
    01 Jul 2024 Jens Eckstein Issued 250,000 $13,750
    Conversion of securities.
    01 Jul 2024 Jakob Dupont Issued 250,000 $13,750
    Conversion of securities.
    01 Jul 2024 Jakob Dupont Exercise 250,000 $13,750
    Conversion of securities. 750,000 - Restricted Stock Units
    01 Jul 2024 Kim Drapkin Issued 250,000 $13,750
    Conversion of securities. As per announcement on 08-07-2024
    01 Jul 2024 Kim Drapkin Exercise 250,000 $13,750
    Conversion of securities. 750,000 - Restricted Stock Units
    19 Apr 2024 Paul Hopper Sell 5,242,277 $381,113
    On-market trade.
    18 Apr 2024 Paul Hopper Sell 4,500,000 $363,600
    On-market trade.
    17 Apr 2024 Paul Hopper Sell 4,380,952 $365,285
    On-market trade.
    01 Feb 2024 Paul Hopper Transfer 10,000,000 $1,000,000
    As advised by the company. Transfer of shares for nil
    consideration.
    01 Feb 2024 Paul Hopper Issued 110,790,024 $1,717,245
    Issue of securities. Subject to release from escrow, as per announcement on 01-02-2024
    01 Feb 2024 Paul Hopper Issued 1,381,422 $21,412
    Issue of securities. Subject to release from escrow, as per announecment on 01-02-2024
    12 Jan 2024 Leslie (Mi Ok) Chong Issued 23,175,000 $2,781,000
    Issue of securities. 23,175,000 - Performance Rights
    12 Jan 2024 Paul Hopper Issued 3,901,500 $468,180
    Issue of securities. 3,901,500 - Performance Rights
    12 Jan 2024 Lesley Russell Issued 1,000,000 $120,000
    Issue of securities. 1,000,000 - RSUs
    12 Jan 2024 Jakob Dupont Issued 1,000,000 $120,000
    Issue of securities. 1,000,000 - RSUs
    12 Jan 2024 Jens Eckstein Issued 1,000,000 $120,000
    Issue of securities. 1,000,000 - RSUs
    12 Jan 2024 Kim Drapkin Issued 1,000,000 $120,000
    Issue of securities. 1,000,000 - RSUs

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Ms Leslie (Mi Ok) Chong Chief Executive OfficerManaging Director Nov 2016
    Ms Chong joined the Group from the leading oncology clinical development company, Genentech (a member of the Roche family), where she was a Senior Clinical Program Lead at the head office in San Francisco. She has over 25 years of experience in leading clinical and department development in oncology. In November 2016, Former directorships in last three years - Cure Brain Cancer Foundation (non-profit organisation), until 11 April 2023.
    Mr Paul Alex Hopper Executive ChairmanExecutive Director Dec 2013
    Mr Hopper has over 20 years of experience in the management and funding of biotechnology and healthcare public companies as chairman, chief executive officer and director in Australia and the United States. Mr Hopper's sector experience has covered therapeutic areas with emphasis on immunotherapy. He also has capital markets experience in equity and debt raisings in Australia, Asia, Europe, and the United States. Former directorships in last three years include Scopus BioPharma Inc (NASDAQ: SCPS), until 18 May 2022.
    Dr Lesley Russell Non-Executive Director Apr 2019
    Dr Russell is a haematologist/oncologist and has over 25 years of experience and leadership in the international pharmaceutical field as a Chief Medical Officer. She has undertaken clinical development in a number of therapeutic areas including haematology/oncology and has had new drug approvals with FDA and European Medicines Agency. Dr Russell has experience as a director of NASDAQ listed pharmaceutical companies. She is a member of the Royal College of Physicians UK. Other current directorships - Enanta Pharmaceuticals (NASDAQ: ENTA), since 22 November 2016. Dr Russell is member of Risk Committee.
    Dr Jakob Dupont Non-Executive Director Sep 2022
    Dr Dupont is an industry and drug development expert with more than 20 years of experience specialising in oncology and other therapeutic areas. Dr Dupont is currently the Executive Venture Partner at Sofinnova Investments. Dr Dupont's experience includes NASDAQ listed Atara Biotherapeutics (NASDAQ: ATRA), where he oversaw all research and development, including three clinical stage programs spanning Phase 1 through to Phase 3, and preclinical programs. Other current directorships include Pyxis Oncology (NASDAQ: PYXS); Avenzo Therapeutics and Flagship Pioneering (Scientific Advisory Board). Former directorships in last three years - Apexigen (NASDAQ: APGN) until August 2023. Dr Dupont is member of the Risk Committee.
    Ms Kim Drapkin Non-Executive Director Jun 2023
    Ms Drapkin has over 25 years of experience working with private and publicly traded biotechnology and pharmaceutical companies, including building and leading finance functions, raising capital, and leading strategic financial planning. In addition to Imugene, Ms Drapkin currently serves on the board of directors at Acumen Pharmaceuticals (NASDAQ: ABOS) where she chairs the audit committee and is a member of the compensation committee and LENZ Therapeutics (NASDAQ: LENZ) where she is a member of the compensation and governance committees. Recently, Ms Drapkin was CEO and a board member at Graphite Bio where she led the strategic alternatives process culminating in a reverse merger with LENZ Therapeutics. Prior to that, Ms Drapkin was CFO at Jounce Therapeutics since its inception, playing a role in building Jounce's financial infrastructure. Prior to joining Jounce, Ms Drapkin owned a financial consulting firm where she served as the interim chief financial officer for early stage biotechnology companies. Previously, Ms Drapkin was chief financial officer at EPIX Pharmaceuticals. Prior to EPIX, Ms Drapkin spent ten years in roles of increasing responsibility within the finance organisation at Millennium Pharmaceuticals. Ms Drapkin began her career in the technology and life sciences practice at PriceWaterhouseCoopers LLP. Other current directorships are held with Acumen Pharmaceuticals (NASDAQ: ABOS); LENZ Therapuetics (NASDAQ: LENZ). Former directorships in last three years - Yumanity Therapeutics (NASDAQ: YMTX); Proteostasis Therapeutics (NASDAQ: PTI). She is chair of risk committee.
    Mr Michael (Mike) Tonroe Chief Financial OfficerCompany Secretary Mar 2023
    -
    Monil Shah Chief Business Officer
    -
    Mike Tonroe Chief Financial Officer
    -
    Michael (Mike) Tonroe Chief Financial OfficerCompany Secretary
    -
    Paul Woodard Chief Medical Officer
    -
    Bradley Glover Chief Operating Officer
    -
    Nicholas Ede Chief Technology Officer
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Paul Hopper 409,071,906 5.57%
    JP Morgan 283,996,697 3.86%
    Citicorp Nominees Pty Limited 266,813,810 3.63%
    Mann Family 265,582,609 3.61%
    HSBC Custody Nominees (Australia) Limited i 213,532,203 2.91%
    Dr Nicolas Smith 118,000,000 1.61%
    Netwealth Investments Limited <Wrap Ser Vices A/C> 85,488,611 1.16%
    Mi Ok Chong 78,416,666 1.07%
    BNP Paribas Noms Pty Ltd 70,407,583 0.96%
    National Nominees Pty Ltd 60,113,645 0.82%
    UBS Nominees Pty Ltd 50,328,041 0.68%
    BNP Paribas Noms Pty Ltd <Ib Au Noms Retail Client> 48,979,324 0.67%
    HSBC Custody Nominees (Australia) Limited ii 29,079,510 0.40%
    Mr Phillip Wood 25,480,000 0.35%
    Sve Capital Pty Ltd <Strategic Vision Unit A/C> 23,000,000 0.31%
    Dr Yuman Fong 22,379,032 0.30%
    Dr Jen Eckstein 20,738,095 0.28%
    Dr Lesley Russell 20,238,095 0.28%
    Citicorp Nominees Pty Limited <Colonial First State Inv A/C> 20,230,709 0.28%
    Jem Investment Fund Holdings Pty Ltd <Jem Invest Fund Family A/C> 20,000,000 0.27%
    Mr Scott Spencer Pappin & Mrs Tracey Lee Pappin <Pappin Super Fund A/C> 20,000,000 0.27%

    Profile

    since

    Note